Tyra Biosciences, Inc. — Cyborg Score 8/10

Strong
Precision Oncology / Biotechnology

Strategic Profile

Tyra has outlined its "dabogratinib 3x3" strategy targeting LG-UTUC, IR NMIBC and achondroplasia, with oral dabogratinib as a potential first-in-class selective FGFR3 inhibitor. CEO Todd Harris narrowed the company's focus to "highest value opportunities" for dabogratinib in three lead areas: low-grade upper tract urothelial carcinoma (UTUC), intermediate-risk non-muscle invasive bladder cancer (NMIBC), and skeletal dysplasias with achondroplasia.

Cyborg Score Rationale

9 analysts recommend buying the stock with a Strong Buy rating. The company holds $256.0 million in cash and marketable securities with stated runway through at least 2027. Key near-term catalysts include SURF302 interim data by end 1H 2026 and BEACH301 safety sentinel results in 2H 2026.

Top Insights

  • Dabogratinib's selectivity is designed to reduce toxicities associated with FGFR1 and FGFR2 inhibition, which have complicated the use of pan-FGFR inhibitors.
  • Full-year 2025 R&D rose to $102.9M with net loss of $119.9M.
  • The company expects to report initial three-month complete response data by end 1H 2026.
  • Average 12-month price target is $43.50 with analyst consensus of Strong Buy (9 buy, 0 sell).

Named Competitors

  • Erdafitinib/FGFR inhibitors — Approved pan-FGFR inhibitor with broader toxicity profile
  • CNP-based therapies for achondroplasia — Established competitor in skeletal dysplasia treatment
  • FGFR3 selective inhibitor programs — Competing FGFR3-selective program with different tolerability profile

Recent Developments

  • (March 2026) Narrowed dabogratinib focus to "3x3" strategy targeting LG-UTUC, IR NMIBC and achondroplasia
  • (March 2026) Reported Q4 and FY 2025 results with $256M cash runway through 2027
  • (February 2026) Multiple analyst upgrades including Wedbush price target raised to $53, Raymond James to $55
  • (February 2026) ASCO GU 2026 presentation of SURF301 metastatic urothelial cancer response and biomarker data

Open the full interactive Tyra Biosciences, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →